References
- Demin, I., Hamrn, B., Luttringer, O., Pillai, G., and Jung, T. (2012), “Longitudinal Model-Based Meta-Analysis in Rheumatoid Arthritis: An Application Toward Model-Based Drug Development,” Clinical Pharmacology and Therapeutics, 92, 352–359.
- FDA Draft Guidance (2014, May), FDA Draft Guidance on Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf.
- FDA Guidance (2015, April), FDA Guidance on Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, available at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
- Larson, R., and Edwards, B. H. (2009), Calculus, Belmont, CA: Brooks/Cole.
- Oehlert, G. W. (1992), “A Note on the Delta Method,” The American Statistician, 46, 27–29.
- Thomas, N., Sweeney, K., and Somayaji, V. (2014), “Meta-Analysis of Clinical Dose–Response in a Large Drug Development Portfolio,” Statistics in Biopharmaceutical Research, 6, 302–317.